BTG3 and in situ carcinoma: Earlier studies considered ANA positivity in MS as a false positive finding [11], or recommended their exclusion during evaluation of clinically isolated syndrome (CIS) and MS, argumenting that their presence in the context of MS was not indicative of an alternative diagnosis, such as a disease from the SARD spectrum [12].